The Prostate Cancer Therapy Research Group is headed by Professor Karl-Henning Kalland and has long experience in advanced molecular studies of gene expression regulation in normal cells, virus-infected cells and cancer cells. Our aim is to:
1) understand signal transduction pathway activation and hierarchies of transcriptional regulation which are associated with important cancer hallmarks of the model. Currently the IL6/STAT3 and WNT/Beta-catenin pathways and the transcription factors androgen receptor (AR), FOXA1, NKX3-1 and TP63 are focused.
2) to develop anti-cancer drugs in innovative combination strategies. Leading compound discovery is coupled to molecular target identification.
3) to identify and isolate circulating cancer cells from peripheral blood of cancer patients. The aim is to examine how malignant cells of our model capture essential features of circulating cancer cells.
Collaborators for Cryoimmunotherapy
Patology – Ole Johan Halvorsen
LKB – Mia Hjelle
Microbiology – Tore Elling Ulvestad
Radium Hospital Department of Cell Therapy- Gunnar Kvalheim
Clinical Research Post- Bjørn Tore Gjertsen, Medical advisor
Urology- Christian Beisland, Principal Investigator
Oncology- Svein Inge Helle
Immunology and transfusion medicine- Einar K. Kristoffersen
The research was supported by Einar Galtung Døsvig, Espen Galtung Døsvig, Jan Einar Greve, Thorstein Selvik, Kåre Rommetveit, Trond Mohn, Herman Friele, Bjarne Rieber, Tordis and Fritz C. Rieber’s legacy, Bergen Research Foundation, Helse Vest (grants 911778, 911626, 911747), the Norwegian Cancer Society.
Miltenyi CliniMACS Prodigy, ABI PRISM ® 7900HT. Sequence Detection System , Agilent 2100 Bioanalyzer instruments, Bio-Tek Cytation 5 Cell Imaging Multi-Mode Reader.